CONCORD, Ontario, Dec. 6, 2017 /PRNewswire/ -- Impopharma, Inc. today introduced a new corporate logo and unveiled an enhanced corporate website (www.impopharma.com) as part of a strategic re-branding to reflect the company's growth and progressive brand vision. This supports the growing need within the specialty pharmaceutical sector for expert product development and testing of pulmonary and nasal products.
"Our new logo gives Impopharma a bright and refined look; one that visually captures our finest qualities — trust, quality and innovation — and reinforces our strategy to become a leading specialty pharmaceutical company," said Theron E. Odlaug, Impopharma Chief Executive Officer and Executive Chairman. "Our new website provides greater opportunity to interact with our many clients and partners; building stronger relationships. In addition, it provides a forum to articulate our specialized development and analytical capabilities," added David Mayers, Impopharma Chief Operating Officer.
Impopharma wants to focus on their excellence in this specialty market. They are able to target this field with a strong vision and identifiable logo. By redesigning the website and logo to incorporate their qualities and new appearance, Impopharma wishes to extend and strengthen reach by serving a broad audience of investors, prospective customers, scientists, and members of the general public.
The website includes updated information of the services, equipment and capabilities emphasizing their expertise since 1995. It also highlights many of Impopharma's achievements and scientific endeavours.
Impopharma is a state-of-the-art FDA & Health Canada approved research and development facility located in Concord, Ontario, Canada. Impopharma specializes in the development of pulmonary and nasal pharmaceutical products in a variety of delivery systems, such as dry powder inhalers, metered dose aerosol inhalers, nasal pumps and nebules. Impopharma also has the ability to develop various spray, topical, and ophthalmic products.
Impopharma has an established, proven track record with many in-house developed products being marketed worldwide.
Vien Brewster, 905-760-0232
Vice President, Finance
SOURCE Impopharma Inc.